[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY2021020I2 - Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη - Google Patents

Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη

Info

Publication number
CY2021020I2
CY2021020I2 CY2021020C CY2021020C CY2021020I2 CY 2021020 I2 CY2021020 I2 CY 2021020I2 CY 2021020 C CY2021020 C CY 2021020C CY 2021020 C CY2021020 C CY 2021020C CY 2021020 I2 CY2021020 I2 CY 2021020I2
Authority
CY
Cyprus
Prior art keywords
delivery system
drug delivery
system consisting
hormonal contraception
tetrahydroxylated estrogen
Prior art date
Application number
CY2021020C
Other languages
English (en)
Other versions
CY2021020I1 (el
Original Assignee
Estetra Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01201945A external-priority patent/EP1293210B1/en
Application filed by Estetra Srl filed Critical Estetra Srl
Publication of CY2021020I2 publication Critical patent/CY2021020I2/el
Publication of CY2021020I1 publication Critical patent/CY2021020I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY2021020C 2001-05-23 2021-07-26 Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη CY2021020I1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01201945A EP1293210B1 (en) 2001-05-23 2001-05-23 Means and method for hormonal contraception
EP01201946 2001-05-23
EP01201947 2001-05-23
EP01204377 2001-11-15
EP02075695 2002-02-21

Publications (2)

Publication Number Publication Date
CY2021020I2 true CY2021020I2 (el) 2021-12-31
CY2021020I1 CY2021020I1 (el) 2021-12-31

Family

ID=27513107

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081100136T CY1108093T1 (el) 2001-05-23 2008-02-04 Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
CY2021020C CY2021020I1 (el) 2001-05-23 2021-07-26 Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20081100136T CY1108093T1 (el) 2001-05-23 2008-02-04 Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη

Country Status (12)

Country Link
US (1) US7732430B2 (el)
EP (1) EP1390042B1 (el)
CA (1) CA2448278C (el)
CY (2) CY1108093T1 (el)
DE (1) DE60223795T2 (el)
DK (1) DK1390042T3 (el)
ES (1) ES2296943T3 (el)
FR (1) FR21C1033I2 (el)
LU (1) LUC00213I2 (el)
NL (1) NL301115I2 (el)
PT (1) PT1390042E (el)
WO (1) WO2002094279A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318092T2 (de) 2002-10-23 2008-11-27 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
US20060211669A1 (en) 2002-11-08 2006-09-21 Verhaar Mark T Synthesis of estetrol via estrone derived steroids
CN103703014A (zh) 2011-06-01 2014-04-02 埃斯特拉公司 用于产生雌四醇中间体的方法
CN103619867B (zh) 2011-06-01 2015-12-23 埃斯特拉公司 用于产生雌四醇中间体的方法
RU2627111C2 (ru) * 2011-07-19 2017-08-03 Пантархей Байосайенс Б.В. Таблетка, содержащая дегидроэпиандростерон (дгэа)
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
ME02723B (me) * 2011-08-11 2017-10-20 Estetra Sprl Upotreba estetrola kao kontraceptivnog sredstva u hitnim slučajevima
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
CA2924255C (en) 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Process for the preparation of estetrol
MX369035B (es) 2013-12-12 2019-10-25 Donesta Bioscience B V Unidad de dosificacion solida de disolucion oral que contiene un componente de estetrol.
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
MA44205B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
ES2877476T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
DK3310333T3 (da) 2015-06-18 2020-06-02 Estetra Sprl Oralt dispergibel doseringsenhed indeholdende en estetrolkomponent
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN115429806A (zh) * 2018-02-07 2022-12-06 埃斯特拉有限责任公司 具有降低的心血管作用的避孕组合物
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
MX2024009584A (es) 2022-02-10 2024-08-14 Estetra Srl Metodos anticonceptivos con efectos de sangrado programado.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
ATE302018T1 (de) 1997-06-20 2005-09-15 Akzo Nobel Nv Gonadotropin releasing hormon antagonist
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
EP1171091A1 (de) 1999-04-16 2002-01-16 Jenapharm GmbH & Co. KG Pharmazeutische oder kosmetische zusammensetzungen zur lokalen, intradermalen applikation von estrogenen
AU5137900A (en) 1999-05-28 2000-12-18 University Of Cincinnati, The Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
DE60129550T2 (de) 2000-05-12 2008-04-10 The Government Of The United States Of America, As Represented By The Department Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
PT1446128E (pt) * 2001-11-15 2007-03-30 Pantarhei Bioscience Bv Utilização de compostos estrogénicos combinados com compostos progestagénicos na terapia hormonal de substituição

Also Published As

Publication number Publication date
LUC00213I2 (el) 2021-10-29
WO2002094279A1 (en) 2002-11-28
ES2296943T3 (es) 2008-05-01
LUC00213I1 (el) 2021-07-08
NL301115I1 (el) 2021-07-14
EP1390042A1 (en) 2004-02-25
FR21C1033I1 (fr) 2021-10-15
CA2448278A1 (en) 2002-11-28
CA2448278C (en) 2010-06-08
NL301115I2 (nl) 2021-10-25
US20040198710A1 (en) 2004-10-07
US7732430B2 (en) 2010-06-08
DK1390042T3 (da) 2008-03-31
PT1390042E (pt) 2008-03-10
CY1108093T1 (el) 2014-02-12
CY2021020I1 (el) 2021-12-31
DE60223795T2 (de) 2008-11-27
FR21C1033I2 (fr) 2022-04-22
DE60223795D1 (de) 2008-01-10
EP1390042B1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
CY2021020I1 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
DE60140462D1 (de) Darreichungsform zur hormonalen kontrazeption
PL370889A1 (en) Vaginal delivery of drugs
NO20041315L (no) Medikamentavleveringssystem
ATE289500T1 (de) Ophtalmologische medikamentenzuführvorrichtung
HUP0700039A2 (en) Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation
DK1473003T3 (da) Lægemiddeladministrationsanordning
EP1367995A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING THE DIFFUSION OF MEDICAMENTS THROUGH AND IN EPITHELIAL TISSUES
EE200100256A (et) Ravimi manustamise vahend, eriti progestiinide jaöstrogeenide manustamiseks
AU2002241538A1 (en) Intrasvascular drug delivery device and use therefor
NO20035645L (no) Forsterket medikamentlevering i transdermale systemer
DK1409065T3 (da) Oftalmisk medikamentafgivelsesanordning
EP1450876A4 (en) INTEGRATED TRANSDERMAL DRUG DELIVERY SYSTEM
ATE311173T1 (de) Neues selbstemulgierendes arzneistoffverabreichungssystem
HK1077523A1 (en) Proliposomal drug delivery system
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
IL137559A0 (en) Transdermal drug delivery system
IL139177A0 (en) Sustained release drug delivery system
HUP0202741A3 (en) Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation
DE10192797D2 (de) Drug-Delivery-Systeme
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
AU2001269439A1 (en) Medicinal preparations for treating sex hormone-dependent diseases
GB0029843D0 (en) Drug delivery system
AU2002311676A1 (en) Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
AU2002311675A1 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception